FRONTEO Starts Joint Research with Tokyo Institute of Technology to Improve Efficiency and Speed ​​of Drug Discovery Target Search

2022.09.29 Press release

--To the press -

FRONTEO Starts Joint Research with Tokyo Institute of Technology to Improve Efficiency and Speed ​​of Drug Discovery Target Search

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Growth)

 FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO), Tokyo Institute of Technology, Institute of Innovative Research, Cellular Engineering Research Center (Location: Midori-ku, Yokohama) and disease structure We are pleased to inform you that we have started joint research on improving the efficiency of analysis and drug discovery target searches.

 

 A research group led by Associate Professor Fumi Kano and Specially Appointed Professor Masayuki Murata of the Center is investigating cellular signal transduction based on quantitative changes in proteins within single cells and their qualitative and spatiotemporal (localization) changes. We are developing the "PLOM-CON analysis method" to elucidate the cell state indicated by disease and drug efficacy1).This analysis method calculates the feature value of each protein based on the amount, quality, and localization information of proteins at the single cell level obtained from big data of fluorescent antibody-stained images of cells, and analyzes their temporal correlation. It visualizes a "covariation network" using strength as an index, and detects protein group information that is responsible for differences and changes in cell state from changes and differences in the network.From this characteristic, drug discovery target search by target protein extraction of drugs whose effect in individuals has been found but the target molecule is unknown, ultra-early characterization of diseased iPS cells and cells differentiated from iPS cells, etc. is expected to be utilized.

 

 In addition, FRONTEO is developing AI drug discovery applications "Cascade Eye" and "liGALILEO" that can comprehensively and non-biasly analyze the structural network of diseases and the scientific evaluation of compounds based on a huge amount of academic paper information using AI. I'm here.

 

 In joint research, the network analysis method based on wet (biological experiments using cells etc.) by the center and FRONTEO's dry (AI analysis based on unstructured information such as medical papers) are based. We plan to work on research and development that contributes to the efficiency and speed of drug discovery target searches through the synergy of network analysis AI technology.

 

1) Tokyo Institute of Technology: Constructing a protein covariation network from cell-stained images Expecting to accelerate drug discovery by developing a new analysis method that vividly captures the "cell state", https://www.titech.ac.jp/news/2021/061334

 


■ About Cascade Eye
 URL:https://lifescience.fronteo.com/aidiscovery/cascade-eye/
"Cascade Eye" uses FRONTEO's natural language analysis AI engine "Concept Encoder" to analyze papers and medical information, and maps molecules and genes related to the disease you want to analyze. ) is an AI system that displays in the shape ofIt visualizes the relationships between molecules and genes, and supports the significant efficiency improvement of the target search process in drug discovery research.Since AI comprehensively searches for a huge amount of information that cannot be read by humans, it is possible to discover new drug discovery targets and the possibility of diverting existing drugs to other diseases without being influenced by researcher bias. It enables drug discovery approaches that were difficult with conventional methods alone, such as discovery and identification of unknown biomarkers.Patent registration number: Patent No. 6915818

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engines "KIBIT", "Concept Encoder (trademark: conceptencoder, reading: concept encoder)", and "Looca Cross", which are specialized in natural language processing. It is a data analysis company that supports the business of companies by extracting meaningful and important information from a huge amount of text data. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support corporate international litigation. Has been deployed.Based on the AI ​​technology cultivated in this business, we will expand the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge", We contribute to solving various corporate issues such as drug discovery support, dementia diagnosis support, financial, personnel, and sales support. Listed on TSE Mothers (currently TSE Growth) on June 2014, 2007. Obtained a first-class medical device manufacturing and sales business license in January 6 (permit number: 26B2021X1), and notified the managed medical device sales business in September of the same year (notification number: 13 Minato Misei Equipment No. 1).The capital is 10350 thousand yen (as of March 9, 3).

* FRONTEO, Cascade Eye, liGALILEO, KIBIT, conceptencoder, and Looca Cross are registered trademarks of FRONTEO in Japan.

 

<Contact information for the press>

Public Relations Officer, FRONTEO Inc.

Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x